

Regimen Reference Order – GENU – cabazitaxel + CARBOplatin

ARIA: GENU – [cabazitaxel + CARBO]

Planned Course: Every 21 days up to 10 cycles

Indication for Use: Prostate Cancer, Metastatic, Castration-Resistant

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

❖ Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GENU – cabazitaxel + CARBOplatin

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Day 1		
predniSONE	10 mg	Orally once in the morning with food (Self-administered at home)
famotidine	40 mg	Orally 1 hour prior to cabazitaxel
cetirizine	10 mg	Orally 30 minutes prior to cabazitaxel
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	8 mg	IV in normal saline 50 mL over 15 minutes
Wait for 30 minutes after completion of IV pre-medications before starting cabazitaxel		
cabazitaxel	20 mg/m ²	IV in normal saline 250 mL over 60 minutes <i>Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter</i>
CARBOplatin	AUC 4 mg/mL.min; maximum dose 600 mg (see table below)	IV in D5W 250 mL over 30 minutes
Days 2 to 21		
predniSONE	10 mg	Orally once daily in the morning with food (Self-administered at home)

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes, bilirubin and PSA as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required after cabazitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
dexamethasone	8 mg	Orally once daily on Days 2 and 3
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- prednisone is a cancer therapy in this treatment regimen. Remind patient to take prednisone at home
- Patients should be advised to contact clinic prior to administration of live or live-attenuated vaccines due to risk of immunosuppression by cabazitaxel
- Patients should be instructed to contact their cancer team if they experience three or more episodes of diarrhea per day
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- LHRH analog treatment (i.e. leuprolide, goserelin) is continued during cabazitaxel and prednisone therapy
- CARBOplatin dose considerations:
 - CCMB Genitourinary DSG uses **actual body weight** to calculate GFR
 - CCMB Genitourinary DSG uses a maximum CARBOplatin dose of 600 mg
 - If calculated CARBOplatin dose differs **more than 10%** from prescribed CARBOplatin dose, contact the prescriber

CARBOplatin Dosing Calculations per CCMB Genitourinary DSG						
Calculation of CARBOplatin dose: (maximum 600 mg)						
Dose (mg) = target AUC (GFR + 25)						
$\text{GFR} = \frac{N \times (140 - \text{age in years}) \times \text{Actual Body Weight (kg)}}{\text{serum creatinine in } \mu\text{mol/L}} = \text{___ mL/min}$						
N = 1.23 in males						
$\frac{\text{AUC (mg/mL.min)}}{4}$	X	<table border="1" style="margin: auto; border-collapse: collapse;"> <tr> <td style="text-align: center; padding: 5px;"> $\frac{\text{GFR} + 25 \text{ (mL/min)}}{\text{___} + 25}$ </td> <td style="text-align: center; padding: 5px;"> = </td> <td style="text-align: center; padding: 5px;"> <table border="1" style="margin: auto; border-collapse: collapse;"> <tr> <td style="text-align: center; padding: 5px;"> Total Dose (mg) </td> </tr> </table> </td> </tr> </table>	$\frac{\text{GFR} + 25 \text{ (mL/min)}}{\text{___} + 25}$	=	<table border="1" style="margin: auto; border-collapse: collapse;"> <tr> <td style="text-align: center; padding: 5px;"> Total Dose (mg) </td> </tr> </table>	Total Dose (mg)
$\frac{\text{GFR} + 25 \text{ (mL/min)}}{\text{___} + 25}$	=	<table border="1" style="margin: auto; border-collapse: collapse;"> <tr> <td style="text-align: center; padding: 5px;"> Total Dose (mg) </td> </tr> </table>	Total Dose (mg)			
Total Dose (mg)						

AUC= Area Under Curve

The estimated creatinine clearance is based on limited evidence. Sound clinical judgment and interpretation of the estimation are required, because the equation may not be appropriate for some patient populations (for example, acute renal failure).